STEVEN I SHERMAN to Biomarkers, Tumor
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Biomarkers, Tumor.
Connection Strength
0.730
-
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221.
Score: 0.147
-
Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
Score: 0.142
-
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61.
Score: 0.113
-
Emerging treatments in thyroid cancer. Clin Adv Hematol Oncol. 2012 Sep; 10(9):594-6.
Score: 0.108
-
Thyroid carcinoma. J Natl Compr Canc Netw. 2005 May; 3(3):404-57.
Score: 0.065
-
Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 2019 04; 29(4):530-539.
Score: 0.042
-
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 03; 41(3):620-622.
Score: 0.039
-
Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid. 2011 Dec; 21(12):1309-16.
Score: 0.026
-
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20.
Score: 0.019
-
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.
Score: 0.011
-
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
Score: 0.009
-
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56.
Score: 0.008